N
The startup develops anti-cancer combination therapies and neutropenia medications to mitigate the side effects of cancer treatments and enhance the efficacy of existing drugs. By targeting the adverse effects associated with cancer therapies, the company aims to improve patient outcomes and quality of life during treatment.
Iksan, South Korea
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops anti-cancer combination therapies and neutropenia medications to mitigate the side effects of cancer treatments and enhance the efficacy of existing drugs. By targeting the adverse effects associated with cancer therapies, the company aims to improve patient outcomes and quality of life during treatment.